Jun 8, 2022 PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
May 23, 2022 PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
Apr 27, 2022 PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
Apr 19, 2022 PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
Apr 13, 2022 PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
Mar 22, 2022 PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
